24/7 Market News Snapshot 14 May, 2025 – Verve Therapeutics, Inc. Common Stock (NASDAQ:VERV)

May 14, 2025

DENVER, Colo., 14 May, 2025 (www.247marketnews.com) – (NASDAQ:VERV) are discussed in this article.
Verve Therapeutics, Inc. (VERV) is experiencing significant trading activity, reflecting strong investor interest and confidence in the company’s innovative approach to genetic medicine for cardiovascular diseases. Following a noteworthy increase of 15.6% in stock price, reaching $4.809 from a prior close of $4.16, the trading volume has surged to 1.39 million shares. This surge may indicate bullish sentiment, encouraging investors to closely monitor key resistance levels above $4.80 and support around $4.55 while considering overarching market dynamics.

The momentum is further bolstered by promising preliminary results from Verve’s Heart-2 Phase 1b clinical trial involving VERVE-102, a groundbreaking treatment aimed at permanently inactivating the PCSK9 gene in the liver. The results demonstrate dose-dependent reductions in low-density lipoprotein cholesterol (LDL-C) and PCSK9 levels, with an impressive mean reduction of 53% and some patients experiencing reductions of up to 69% after a single infusion. Dr. Sekar Kathiresan, co-founder and CEO, highlighted the transformative potential of VERVE-102, indicating a shift in cardiovascular disease management from chronic therapies to a singular, potentially life-altering dose.

While VERVE-102 generates excitement, Verve is also progressing with its Pulse-1 Phase 1b clinical trial for VERVE-201, which targets the ANGPTL3 gene, with updates expected in the latter half of 2025. With approximately $500 million in cash and marketable securities, Verve remains financially equipped to support its operations into mid-2027. The upcoming Phase 2 clinical trial for VERVE-102 will initiate within the next few months, with further updates anticipated regarding the Heart-2 trial and collaboration on the PCSK9 program, positioning Verve Therapeutics as a leader in redefining treatment strategies for cardiovascular disease.

Related news for (VERV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.